Array BioPharma v. Sandoz: Six MEK Inhibitor Patents Settled in Delaware
Array BioPharma filed suit against Sandoz in Delaware District Court asserting six patents covering MEK inhibitor compounds, compositions, and formulations. The case resolved after 826 days via a settlement and license agreement, with Sandoz agreeing not to commercialise its accused ANDA product except as permitted under that agreement.
Hatch-Waxman MEK inhibitor dispute ends in licensed settlement
Array BioPharma Inc. filed this action on 6 October 2022 in the District of Delaware before Judge Gregory B. Williams, asserting infringement of six US patents — US9314464B2, US9850229B2, US10005761B2, US9562016B2, US9598376B2, and US9980944B2 — covering compounds, compositions, and formulations used as MEK protein kinase inhibitors. The suit was triggered by Sandoz’s ANDA filing and associated Paragraph IV certifications, a classic Hatch-Waxman mechanism that allows branded pharmaceutical companies to sue generic entrants before market launch.
The case closed on 9 January 2025 via a stipulated dismissal without prejudice, entered after the parties executed a settlement and license agreement. Critically, the stipulation constrains Sandoz from making, using, offering for sale, or selling the accused generic product in the United States except as the licence permits, and the court retains jurisdiction to enforce both the dismissal order and the underlying agreement. The dismissal is explicitly not an adjudication on the merits.
At 826 days, the litigation ran longer than many ANDA settlements, suggesting the parties required significant negotiation time to agree licence terms — possibly including a launch date, royalty structure, or field-of-use restrictions, though the public record does not disclose these specifics. The preservation of Sandoz’s Paragraph IV certifications and FDA’s ability to grant final ANDA approval indicates the licence likely includes a future-dated or conditional market entry provision, a structure common in branded-generic MEK inhibitor settlements.
Filing to Dismissed without Prejudice in 826 days
826 days — above average for a pharma Hatch-Waxman ANDA case pre-trial resolution
Dismissed without prejudice: what the settlement and licence mean
Dismissal without prejudice following a settlement and licence
A dismissal without prejudice means the court has not ruled on the merits — neither party has been adjudicated to have won or lost. The stipulation was entered jointly and approved by the court, which retains jurisdiction to enforce its terms. The operative constraint on Sandoz flows not from any court judgment but from the contractual licence agreement, making that private document the true governing instrument going forward.
No merits adjudicationArray secures commercial control over generic entry
Array BioPharma achieves its primary litigation objective: Sandoz cannot launch its accused generic product in the US except on terms Array has agreed to. The six patents-in-suit remain unchallenged by any court ruling, preserving their enforceability and potential deterrent value against other ANDA filers. The licence agreement likely provides Array with revenue from any permitted generic entry, turning a litigation adversary into a commercial partner.
Patents intact, entry controlledSandoz retains its ANDA and Paragraph IV certifications
The stipulation expressly preserves Sandoz’s Paragraph IV certifications and does not prohibit the FDA from granting final ANDA approval. This is commercially significant: Sandoz retains a regulatory pathway to market and, under the licence, a contractual right to commercialise the product at an agreed point or on agreed conditions. The costs-each-bear-own provision avoids any financial penalty, and no injunction was issued by the court.
ANDA preserved, licensed entry likelyLicence structure signals a controlled generic launch ahead
The explicit preservation of the ANDA pathway and FDA approval route, combined with a settlement and licence agreement, is consistent with an authorised generic or future-entry licence arrangement common in MEK inhibitor and broader oncology Hatch-Waxman cases. Competitors and market watchers should monitor FDA’s final approval of Sandoz’s ANDA as a signal of when licensed entry may occur. Other potential ANDA filers face a higher practical barrier, as Array has demonstrated willingness to litigate all six patents.
Authorised entry window likelyFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Array BioPharma, Inc. | Company | Pharmaceutical company — holder of US9314464B2 and five related MEK inhibitor patentsSearch in Eureka ↗ |
| Defendant | Sandoz, Inc. | Company | Generic pharmaceutical company filing ANDA with Paragraph IV certification against Array’s MEK inhibitor patentsSearch in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Array BioPharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Megan Elizabeth Dellinger | Attorney | Counsel for Array BioPharma, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Array BioPharma, Inc.Search in Eureka ↗ |
| Defendant counsel | Alexis S. White | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | Dominick T. Gattuso | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | Laura A. Lydigsen | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | Mark H. Remus | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant law firm | Heyman Enerio Gattuso & Hirzel, LLP | Law Firm | Representing Sandoz, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Gregory B. Williams | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated dismissal order is explicit that it ‘shall not act as an adjudication on the merits,’ meaning no finding of infringement, validity, or enforceability was made by the court. The operative legal effect derives entirely from the private settlement and licence agreement. The court’s retention of jurisdiction is the sole judicial mechanism preserving enforcement rights. For patent watchers, the absence of a merits ruling means all six patents emerge from this litigation with their validity and scope legally uncontested — a clean slate for enforcement against future challengers.
US9314464B2 and five related MEK inhibitor patents
The six patents-in-suit — US9314464B2, US9850229B2, US10005761B2, US9562016B2, US9598376B2, and US9980944B2 — collectively cover the compound, composition, preparation, and formulation dimensions of a MEK (mitogen-activated protein kinase kinase) inhibitor therapeutic. MEK inhibitors are a clinically important class of small-molecule oncology drugs targeting the RAS-RAF-MEK-ERK signalling pathway. The patents stem from application filings spanning 2013 to 2017, reflecting a deliberate portfolio-building strategy around a core therapeutic asset.
Holding six patents across multiple claim types — compound, formulation, preparation, and composition — creates overlapping layers of exclusivity that are structurally difficult for a generic challenger to design around in a single ANDA filing. This multi-patent approach is strategically significant in oncology, where the commercial window for branded products is compressed by aggressive generic competition. Any company developing a MEK inhibitor formulation or pursuing an ANDA referencing a product covered by these patents should conduct thorough freedom-to-operate analysis across all six, as each addresses a distinct axis of the technology.
Should you run an FTO against these six MEK inhibitor patents?
Any pharmaceutical company developing a MEK inhibitor compound, formulation, or composition for the US market — whether via an ANDA, 505(b)(2), or novel drug application — should treat these six patents as a primary FTO target. The portfolio spans compound identity, preparation routes, and finished dosage formulations, meaning a product can potentially infringe multiple patents even if it differs in one dimension. The settlement here did not invalidate or disclaim any claims, leaving the full scope intact and enforceable against new entrants.
PatSnap Eureka’s FTO Search Agent can map your compound’s structural and formulation profile against the claim scope of all six patents simultaneously, flagging overlap risk at the claim level rather than the abstract patent level. Eureka can also surface prior art and prosecution history that may inform design-around strategies or inter partes review petitions — critical intelligence before any Paragraph IV certification or ANDA submission targeting an Array BioPharma reference product.
Run a freedom-to-operate analysis on US9850229B2 to assess your product’s exposure
Run FTO in Eureka →Similar MEK inhibitor ANDA patent cases in Delaware and beyond
Explore Hatch-Waxman ANDA patent disputes involving MEK inhibitors and oncology small molecules litigated in Delaware District Court and related venues.
What this case signals for the MEK inhibitor IP landscape
Six patents, one settlement, and a preserved ANDA — the outcome shapes the competitive dynamics for MEK inhibitor generics in the US.
Array’s six-patent stack creates a durable enforcement posture
Asserting six patents across compounds, compositions, and formulations significantly raises the cost and complexity for any generic challenger. No patent was invalidated or held unenforceable here, meaning the full portfolio survives intact. Future ANDA filers targeting the same MEK inhibitor must address each of these patents — a deliberate layered strategy common in oncology small-molecule portfolios.
Court-retained jurisdiction is an enforcement lever worth noting
The Delaware court retaining jurisdiction over the settlement and licence agreement is standard but consequential. If Sandoz deviates from agreed commercialisation terms, Array can seek enforcement directly in federal court without filing a new action. This mechanism gives Array practical control over any future breach and reduces the litigation cost of re-entry into dispute.
Array v Sandoz — key questions answered
Array BioPharma asserted six US patents: US9314464B2, US9850229B2, US10005761B2, US9562016B2, US9598376B2, and US9980944B2. All six cover aspects of MEK protein kinase inhibitor compounds, compositions, preparations, and formulations. The suit was filed on 6 October 2022 in the District of Delaware following Sandoz’s ANDA submission with Paragraph IV certifications.
The case was dismissed without prejudice on 9 January 2025 after the parties entered a settlement and licence agreement. The court retained jurisdiction to enforce both the dismissal order and the licence. Sandoz is restricted from commercialising the accused product in the US except as permitted under the licence. The order is not an adjudication on the merits, and Sandoz’s Paragraph IV certifications were preserved.
The Delaware District Court retaining jurisdiction means Array BioPharma can seek court enforcement of the settlement and licence agreement without filing a new lawsuit if Sandoz violates its terms. This is a standard provision in Hatch-Waxman settlements that gives the patent holder an expedited enforcement mechanism and provides both parties certainty that disputes over the agreement will be resolved in the same court.
The stipulation preserves Sandoz’s Paragraph IV certifications and does not prevent the FDA from granting final ANDA approval, suggesting a licensed market entry may be possible in future. However, Sandoz may not make, use, offer for sale, or sell the accused product in the US except as provided in the private settlement and licence agreement, the terms of which are not publicly disclosed.
Dismissed without prejudice means no court ruling was made on whether the patents are valid, infringed, or enforceable. All six patents-in-suit emerge from the litigation with their legal status unchanged — they remain granted and enforceable US patents. The order explicitly states it shall not act as an adjudication on the merits, meaning any future ANDA challenger must mount its own validity or non-infringement challenge from scratch.
PatSnap Eureka searches patents and litigation data to answer instantly.